ACE and systemic sclerosis: Since the introduction of the angiotensin-converting enzyme inhibitors (ACEIs), SRC has become a less frequent terminal event in patients with SSc.8,46 In the present cohort, SRC accounted for 8.7% of all deaths despite the ACEI treatment.